ASX-listed biotechnology company PharmAust has filed a patent for the use of its monepantel anti-cancer drug to treat viral diseases, having previously said the drug had a positive anti-viral effect on cultured cells infected with COVID-19. The company is developing monepantel as a novel, safe and effective treatment for cancer in humans and animals and is also testing its efficacy in neurodegenerative disease.
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
21 Jun 2024
PharmAust taps investors for $10m
31 May 2024
Shares rise following Thurn return
17 May 2024
Board Moves May 17, 2024
17 May 2024
PharmAust receives FDA approval
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX